A plain-language review of what the published HPS literature says about transplant recipients, chemotherapy patients, people on chronic corticosteroids, and people living with HIV as risk groups, and how immunocompromised readers should approach the CDC rodent-cleanup protocol in 2026.
Every time hantavirus is in the news, one of the first questions asked of WHO, CDC and ECDC briefers is whether immunocompromised patients should change behaviour or change plans. The 2026 MV Hondius cluster has been no exception. At least one of the confirmed European cases is known to have multiple comorbidities, and the question of whether immune status independently affects outcome is on the table at every briefing. The honest answer is that the published evidence is thinner than the public assumption, but the operational read is still meaningful.
Hantavirus pulmonary syndrome (HPS) is, mechanistically, a disease of the pulmonary capillary endothelium. Andes virus and Sin Nombre virus both preferentially infect the endothelial cells that line the small blood vessels of the lung. After an asymptomatic incubation of one to eight weeks, infected patients enter a flu-like prodromal phase of fever, severe myalgia and headache. The defining cardiopulmonary phase begins three to seven days later, when virus-driven endothelial dysfunction causes a rapid capillary leak: protein-rich fluid floods into the alveolar spaces, the lungs become heavy and stiff, gas exchange collapses, and cardiac output falls. The pathology is a low-pressure pulmonary oedema rather than the high-pressure oedema of acute heart failure, and that distinction matters because the supportive-care toolkit is different.
The most rigorous cohort-level analyses of HPS comorbidities come from the long-running Argentine Patagonia Andes virus cohort and the US Sin Nombre virus cohort assembled by the CDC and state health departments since 1993. In both, age over fifty and time-to-hospitalisation are the dominant predictors of mortality. Solid-organ transplant, active chemotherapy, and chronic high-dose corticosteroid use appear as risk markers in individual case reports but have not consistently emerged as independent predictors in pooled analyses. Part of that null result is real, and part is statistical power: HPS is rare, the published cohorts include fewer than two thousand cases across the Americas over thirty years, and immunocompromised individuals are a small subset of any such cohort.
There are three mechanistic reasons immunocompromise could plausibly worsen HPS outcomes even in the absence of a strong epidemiological signal. First, the early antibody and cellular response is part of how peak viraemia is brought under control; impaired responses could mean a higher peak viral load and a more severe capillary leak. Second, the cardiopulmonary phase is also driven by an exuberant cytokine response in some patients, and patients on biologic immunomodulators have presentations that may look qualitatively different. Third, supportive care during the acute phase is mechanically demanding — intubation, ECMO in the most acute cases — and patients who enter that phase with diminished reserve from cancer treatment, transplant immunosuppression, or HIV-related comorbidity are starting the hardest days of the disease from a worse baseline.
Immunocompromise is not one thing. Solid-organ transplant recipients on chronic calcineurin-inhibitor plus mycophenolate plus low-dose steroid regimens are at a meaningfully different baseline from a virologically suppressed person living with HIV with a normal CD4 count on antiretroviral therapy. Patients on active cytotoxic chemotherapy in a neutropenic phase are at a different baseline still. The clinical-risk concern in HPS is concentrated in the solid-organ transplant, active-chemotherapy, and chronic-high-dose-steroid populations, with people living with HIV on suppressive ART and a normal CD4 count carrying essentially baseline risk.
For solid-organ transplant recipients, patients on active chemotherapy, and people on chronic high-dose corticosteroids, delegating rodent cleanup to another adult using full PPE is the lowest-risk option. CDC does not formally restrict immunocompromised adults from performing cleanup if the protocol is followed exactly, but the marginal benefit of delegation is meaningful and the marginal cost is small.
If delegation is not possible, open doors and windows for at least 30 minutes before entering any closed-up space with signs of rodent activity. This single step does more to reduce inhalation exposure than any other element of the protocol.
A NIOSH-approved N95 respirator is the minimum face-piece for hantavirus cleanup. The user-seal-check at the start of cleanup matters: cup both hands gently over the mask, inhale sharply, and feel for any leak around the edges. If you have a pulmonary comorbidity that may interact with respirator tolerance, discuss this with your clinician before the task.
Spray any visible droppings, urine staining or nesting material with a 1:10 bleach solution or an EPA-registered disinfectant and allow at least five minutes of contact time before any wiping. Never dry-sweep or dry-vacuum a contaminated space — both actions aerosolise virus-laden particles that an N95 can reduce but not eliminate.
Place contaminated material in a kitchen-sized bag, wipe the outside of that bag with disinfectant, and place the sealed inner bag inside a heavy contractor bag. Wash hands and forearms thoroughly with soap and water after removing PPE, and launder any reusable outer clothing on a hot cycle.
The hantavirus incubation period is roughly one to eight weeks, with most cases declaring themselves at two to four weeks. The earliest symptoms — fever, severe muscle aches, headache, fatigue, gastrointestinal upset — overlap with many common complaints in patients on immunosuppressive therapy, which is why telling your treating physician about a rodent exposure matters even when no acute symptoms are present: it changes the index of suspicion and the speed of escalation if you do later develop respiratory symptoms. The red-flag transition is to the cardiopulmonary phase: new shortness of breath, cough, low blood pressure, or rapidly worsening fatigue. These are emergency-department symptoms in this context, and an immunocompromised patient with these symptoms after a possible rodent exposure should not delay evaluation.
As of May 19, 2026, the MV Hondius cluster total stands at 12 cases (9 PCR-confirmed Andes virus, 2 probable, 1 inconclusive) and 3 deaths. All approximately 122 repatriated passengers and crew are in WHO-recommended 42-day active monitoring across roughly 20 countries; Day 7 of that monitoring window is today. WHO and ECDC continue to assess the risk to the general public — including immunocompromised readers who were not on the ship and are not in close contact with a confirmed case — as low. There are no travel restrictions related to the cluster. Immunocompromised travellers planning trips to Andes virus endemic regions (rural Patagonia, southern Chile) or Sin Nombre virus endemic regions (the US Four Corners and parts of California and the Pacific Northwest) should coordinate a pre-trip risk-reduction plan with their treating physician.
→ See the live MV Hondius tracker, full timeline and global news sourcesThe published HPS literature does not establish immunocompromise as an independent predictor of fatal outcome at the population level. The strong predictors remain older age, male sex, smoking history, and delayed presentation. Mechanistically, however, an impaired antibody and cellular response in the early viraemic phase could plausibly produce higher peak viraemia and a steeper capillary leak, and immunocompromised patients enter the most dangerous days of the disease from a worse baseline reserve.
Delegating rodent cleanup to another adult using full PPE is the lowest-risk choice for solid-organ transplant recipients, patients on active chemotherapy, and people on chronic high-dose corticosteroids. CDC does not formally restrict immunocompromised adults from performing cleanup if the protocol is followed exactly, but the marginal benefit of delegation is meaningful.
People living with HIV who are virologically suppressed on antiretroviral therapy with a normal CD4 count are at no measurably increased risk of severe HPS. People with advanced HIV (CD4 below 200) or untreated HIV plausibly fall into the broader immunocompromised category and should be counselled accordingly.
WHO and CDC do not recommend travel restrictions for immunocompromised travellers to Andes virus endemic regions. The practical risk-reduction list is to avoid rural cabins that have been unoccupied for prolonged periods without ventilation, to wet-disinfect rather than dry-sweep any rodent-contaminated space, and to coordinate with your treating physician on a continuity-of-care plan and a low threshold for evaluation if febrile symptoms develop.
For any immunocompromised patient who develops fever, severe muscle aches, or shortness of breath within eight weeks of a possible hantavirus exposure, the right action is a same-day medical evaluation with an explicit travel and exposure history declaration. Tell the triage team about both the exposure and the immunocompromise. A low threshold for evaluation is the single highest-yield intervention.